Although in vitro study has shown that ASCT2 antagonist BenSer can suppress melanoma cell proliferation via cell cycle arrest and mTOR inhibition, this compound is not yet available in the clinic and its toxicity is unknown. This evidence concerns the gene SLC1A5 and melanoma.